HRAS mutation

Mutations in NF1 and ROS1 that produce a neoantigen were also linked to improved outcomes. These results support the reproducibility of TMB estimation and highlight the added value of neoantigen profiling in predicting immunotherapy benefits in melanoma.

BRAF-mut PTC is associated with a pro-inflammatory TME milieu compared to BRAF-wt PTC. However, in this limited data set, treatment choice was not associated with differences in OS in BRAF-mut PTC.

P1, N=31, Not yet recruiting, M.D. Anderson Cancer Center

P1/2, N=30, Recruiting, Changhai Hospital | Trial completion date: Mar 2025 --> Dec 2028 | Trial primary completion date: Dec 2024 --> Jun 2027

The data obtained indicates the necessity of genetic testing for all patients suspected of SFMS to determine the individual risk of comorbidities and to form a personalized plan for dynamic follow-up. https://www.crd.york.ac.uk/PROSPERO/view/CRD420251085872, identifier CRD420251085872.

In this Middle Eastern cohort, no consistent molecular or clinical disparities across most parameters. These findings suggest the timing of metastasis may not independently influence prognosis and highlight the relevance of individualized, biology-driven management strategies.

Patients with HRAS-mutant PPGL have higher plasma metanephrine levels and a higher risk of IHI and ICU transfer, which therefore requires personalized perioperative managements.

These findings yield valuable insights into the biological and clinical behaviors of this rare parotid gland neoplasm. Furthermore, this work enhances the understanding of the epidemiological characteristics and optimal management strategies for parotid gland SCNC.

Additionally, a FOXK1::GRHL1 fusion was found in the case of trichogerminoma. Clinical follow-up (15/16 patients; 94%; median: 65 months; range 2.5-106.5 months) showed no evidence of residual or metastatic disease.

WT and mutant proteins adopt distinct conformational ensembles on the membrane, enabling structure-based prediction of allosteric pockets at the protein-membrane interface. These findings offer a mechanistic basis for the H1047R enhanced membrane-binding ability and insights for new therapeutic strategies targeting the protein-membrane interface.

Treatment with chemotherapy consisted of vincristine, dactinomycin, and cyclophosphamide, and received 8 cycles of photon beam radiation. Radiological surveillance up to 12 months showed no signs of recurrence or metastatic lesions. Patients with CS are at a high risk of developing rhabdomyosarcoma and clinicians should be vigilant in the context of any clinical orbital signs of disease.

Although not significantly different, CDKN2A and CDKN2B alterations were more frequent in MECA, while PIK3CA alterations were more frequent in EMC. Overall, EMC and MECA had both overlapping and unique molecular alterations that have potential for targeted therapies.